Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. on May 21, 2013. The filing announces the closing of a public offering of common stock. Note: The request metadata lists "Bio Green Med Solution, Inc.", but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
The filing details a capital raise event rather than operational financial performance metrics such as revenue or profit.
- Shares Sold: 6,833,334 shares of common stock (including 166,667 shares from the underwriters' over-allotment option).
- Offering Price: $3.00 per share.
- Total Gross Proceeds: Approximately $20.5 million (calculated as 6,833,334 shares x $3.00).
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes
The primary material change is the increase in outstanding common stock and the influx of capital resulting from the closing of the public offering on May 21, 2013. No comparative period data is provided in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers regarding internet address information. The document focuses solely on the execution of the stock sale.
Investor Verification Checklist
- Verify the exact net proceeds after deducting underwriting discounts and commissions, as only the gross price per share is listed.
- Confirm the updated total number of shares outstanding post-offering.
- Review the attached Exhibit 99.1 (Press Release) for details on the intended use of proceeds.
- Check subsequent filings for the impact of this capital raise on the company's liquidity and cash position.